Compare ITRI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRI | ABCL |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 1996 | 2020 |
| Metric | ITRI | ABCL |
|---|---|---|
| Price | $97.20 | $9.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $128.56 | $18.69 |
| AVG Volume (30 Days) | 656.7K | ★ 2.8M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.48 | 10.91 |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $2,367,194,000.00 | $75,128,000.00 |
| Revenue This Year | $0.43 | N/A |
| Revenue Next Year | $6.08 | $13.74 |
| P/E Ratio | $24.58 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $77.77 | $2.75 |
| 52 Week High | $108.20 | $14.98 |
| Indicator | ITRI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 33.61 |
| Support Level | $96.13 | $3.45 |
| Resistance Level | $101.87 | $12.91 |
| Average True Range (ATR) | 2.89 | 0.84 |
| MACD | -0.33 | -0.22 |
| Stochastic Oscillator | 32.03 | 1.84 |
Itron Inc provides solutions that measure, manage, and analyze energy and water use. The company offers grid edge intelligence, energy and water management, smart city applications, Industrial Internet of Things (IIoT), and critical infrastructure and related services. It operates under the Itron brand and has four reportable segments: Device Solutions, Networked Solutions, Resiliency Solutions, and Outcomes. Key revenue is generated from the Networked Solutions segment, which includes a combination of communicating endpoints (e.g., smart meters, modules, endpoints, and sensors), network infrastructure, network design services, and associated headend management and application software designed and sold as a complete solution for acquiring and transporting robust application-specific data.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.